Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

y the European Medicines Agency (the "EMA") based on the pixantrone (PIX 301) phase III study results.  

For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com, and www.clinicaltrials.gov.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert<
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of ... transformation in the pain market, according to a ... Inc., a firm providing market research and consultation ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... change for hydrocodone combination products from Schedule III ...
(Date:10/22/2014)... Oct. 22, 2014   Reproductive Medicine Associates ... in the field of infertility, presents new clinical ... screening. The research abstract, released during the 70 ... (ASRM) meeting in Honolulu, Hawaii ... gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... UPI ), a medical device company that develops, ... announced today that David Kaysen, President and CEO, and Medi ... strategy and financial results at the Sixth Annual JMP Securities ... 2011 at The St. Regis Hotel in New York. ...
... Reportlinker.com announces that a new market research report is ... The Global Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... The global generics market is estimated at about $225 ... the value of the total global generics sector will ...
Cached Medicine Technology:Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:10/25/2014)... 2014 Background: , In 1998 Bob ... is a pioneer in the field of establishing recovery community ... treatment system and when he retired, he set out to ... public service. , 1. Where are the ... them? , 2. Can the recovery community be organized ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... ... ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’. ... ... of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced ...
... fewer attacks per year, save millions in health costs, ... If all states banned smoking in restaurants, offices and ... from heart attacks would drop by more than 18,000 ... bans have been implemented in some states, but not ...
... explanation for the difference, study says , THURSDAY, May ... common form of stroke has decreased significantly among whites ... new regional survey designed to be representative of the ... Greater Cincinnati/Northern Kentucky Stroke Study showed an overall drop ...
... from The University of Texas MD Anderson Children,s Cancer Hospital ... patients increased the survival of children with rare tumors in ... issue of the Journal of Pediatric Surgery , looked ... aggressive pediatric cancer known as desmoplastic small round cell tumor ...
... Montreal, May 20, 2010 The results of a ... by Dr. Jean-Claude Tardif are now available in the journal ... of the MHI Research Centre, as well as a professor in ... at the Universit de Montral. The promising findings of ...
... ... Association (NRPA) is reminding Americans to take the proper steps to ensure that their local ... Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) May ...
Cached Medicine News:Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 2Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 3Health News:Big Decline in Heart Attacks If All States Had Smoking Bans 2Health News:Stroke Incidence Down, But Not for Blacks 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: